Xilong Scientific's strong revenue growth might underperform the broader industry, leading to a low P/S ratio. Limited growth rates are expected to persist, reducing investors' willingness to pay for the stock. If recent trends continue, a share price reversal seems unlikely.

Xilong Scientific's future revenue performance is expected to dwindle, keeping the P/S suppressed. Its weak share price has pulled its P/S back below other Chemicals companies. Investors expect limited growth rates to continue, willing to pay a reduced amount for the stock. Unless medium-term conditions improve, they will continue to form a barrier for the share price.

Market confidence in Xilong Scientific's future revenue performance appears diminished with a low P/S ratio and weak share price. Continuation of moderate revenue growth trends may not spurn a reversal in share price. Investors doubt enough potential for revenue improvement to justify a higher P/S ratio.

The strong revenue growth of Xilong Scientific is promising, suggesting that there could be more potential growth ahead. The current stock performance indicates an improved trend and deserves attention for potential investing opportunities.